Latest Advances

  • Condition: Neuromyelitis Optica
  • Journal: Folia medica
  • Treatment Used: Intravenous Gamma Globulin
  • Number of Patients: 1
  • Published —
The study researched the outcomes of intravenous gamma globulin in treating neuromyelitis optica.
  • Condition: Pregnancy in Neuroimmunologic Disorders
  • Journal: Neurology(R) neuroimmunology & neuroinflammation
  • Treatment Used: Rituximab (RTX)/Ocrelizumab (OCR)
  • Number of Patients: 81
  • Published —
The study researched the outcomes of rituximab (RTX)/ocrelizumab (OCR) in women who are pregnant with neuroimmunologic disorders.
  • Condition: Bilateral ARCO Stage II Steroid-Associated Osteonecrosis of the Femoral Head
  • Journal: Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc
  • Treatment Used: Repetitive 1.6 ATA Hyperbaric Oxygen Therapy
  • Number of Patients: 1
  • Published —
This study presented a case of a 36-year-old female diagnosed with bilateral early stage ARCO stage II steroid-associated osteonecrosis (SAON) caused by steroid therapy for neuromyelitis optica spectrum disorder (NMOSD) who was treated with repetitive 1.6 ATA hyperbaric oxygen (HBO2) therapy.
  • Condition: Patients with Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic
  • Journal: Brain and nerve = Shinkei kenkyu no shinpo
  • Treatment Used: Continuing Current Immunotherapy Treatment
  • Number of Patients: 0
  • Published —
This article discusses the treatment of patients with multiple sclerosis, neuromyelitis optica spectrum disorders, and myasthenia gravis during the COVID-19 pandemic.
  • Condition: Neuromyelitis Optica Spectrum Disorders
  • Journal: Scientific reports
  • Treatment Used: Mycophenolate Mofetil Therapy
  • Number of Patients: 1047
  • Published —
The study researched the outcomes of mycophenolate mofetil therapy for patients with neuromyelitis optica spectrum disorders.
  • Condition: Neuromyelitis Optica Spectrum Disorder (NMOSD) During the COVID-19 Pandemic
  • Journal: Therapeutics and clinical risk management
  • Treatment Used: Disease-Modifying Therapies (DMTs)
  • Number of Patients: 0
  • Published —
This study examined neuromyelitis optica spectrum disorder (NMOSD) disease-modifying therapies (DMTs) during the COVID-19 pandemic.
  • Condition: Recurrent Optic Neuritis Associated with Aquaporin (AQP) 4 Antibody Seropositive Neuromyelitis Optica (NMO-ON)
  • Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • Treatment Used: Intravenous Methylprednisolone Pulse (IVMP) Therapy
  • Number of Patients: 35
  • Published —
This study observed the effects of intravenous methylprednisolone pulse (IVMP) therapy on the recovery of visual acuity and its influencing factors in patients with the relapse of aquaporin (AQP) 4 antibody positive neuromyelitis optica related optic neuritis (NMO-ON).
  • Condition: Neuromyelitis Optica Spectrum Disorder
  • Journal: Neurology(R) neuroimmunology & neuroinflammation
  • Treatment Used: Inhibition of IL-6 Activity
  • Number of Patients: 0
  • Published —
The study researched the outcomes of inhibition of IL-6 activity in patients with neuromyelitis optica spectrum disorder.
  • Condition: Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
  • Journal: Scientific reports
  • Treatment Used: Disease Modifying Drugs
  • Number of Patients: 62
  • Published —
The study researched patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders.
  • Condition: Retinal and Brain Damage during Multiple Sclerosis (MS)
  • Journal: Scientific reports
  • Treatment Used: Disease-Modifying Therapies and Steroids
  • Number of Patients: 161
  • Published —
This study quantified the impact of focal inflammatory activity on the rate of neuro-axonal injury over the course of multiple sclerosis (MS) disease.
  • Condition: Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Journal: Neurology(R) neuroimmunology & neuroinflammation
  • Treatment Used: Disease-Modifying Therapy
  • Number of Patients: 67
  • Published —
This study tested the safety and efficacy of using azathioprine, mycophenolate mofetil, or rituximab to treat patients with aquaporin-4 antibody-positive NMOSD.
  • Condition: Central Nervous System Demyelinating Diseases During the Coronavirus Disease 2019 Pandemic
  • Journal: Arquivos de neuro-psiquiatria
  • Treatment Used: Management Strategies
  • Number of Patients: 0
  • Published —
This article discusses management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic.
Showing 1-12 of 55